SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Fryknäs Mårten)) srt2:(2020-2024)
 

Search: (WFRF:(Fryknäs Mårten)) srt2:(2020-2024) > Targeting aggressiv...

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide

Byrgazov, Konstantin (author)
Oncopeptides AB, Luntmakragatan 46, SE-11137 Stockholm, Sweden.;St Anna Childrens Canc Res Inst CCRI, Vienna, Austria.
Andersson, Claes (author)
Uppsala universitet,Cancerfarmakologi och beräkningsmedicin
Salzer, Benjamin (author)
St Anna Childrens Canc Res Inst CCRI, Vienna, Austria.
show more...
Bozsaky, Eva (author)
St Anna Childrens Canc Res Inst CCRI, Vienna, Austria.
Larsson, Rolf (author)
Uppsala universitet,Cancerfarmakologi och beräkningsmedicin
Gullbo, Joachim (author)
Oncopeptides AB, Luntmakragatan 46, SE-11137 Stockholm, Sweden.
Lehner, Manfred (author)
St Anna Childrens Canc Res Inst CCRI, Vienna, Austria.
Lehmann, Fredrik (author)
Oncopeptides AB, Luntmakragatan 46, SE-11137 Stockholm, Sweden.
Slipicevic, Ana (author)
Oncopeptides AB, Luntmakragatan 46, SE-11137 Stockholm, Sweden.
Kager, Leo (author)
Med Univ Vienna, St Anna Childrens Hosp, Dept Pediat, Vienna, Austria.;CCRI, Vienna, Austria.
Fryknäs, Mårten (author)
Uppsala universitet,Cancerfarmakologi och beräkningsmedicin
Taschner-Mandl, Sabine (author)
St Anna Childrens Canc Res Inst CCRI, Vienna, Austria.
show less...
Oncopeptides AB, Luntmakragatan 46, SE-11137 Stockholm, Sweden;St Anna Childrens Canc Res Inst CCRI, Vienna, Austria. Cancerfarmakologi och beräkningsmedicin (creator_code:org_t)
2020-07-29
2020
English.
In: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. - : SAGE PUBLICATIONS LTD. - 1758-8340 .- 1758-8359. ; 12
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: Low survival rates in metastatic high-grade osteosarcoma (HGOS) have remained stagnant for the last three decades. This study aims to investigate the role of aminopeptidase N (ANPEP) in HGOS progression and its targeting with a novel lipophilic peptidase-enhanced cytotoxic compound melphalan flufenamide (melflufen) in HGOS. Methods: Meta-analysis of publicly available gene expression datasets was performed to determine the impact ofANPEPgene expression on metastasis-free survival of HGOS patients. The efficacy of standard-of-care anti-neoplastic drugs and a lipophilic peptidase-enhanced cytotoxic conjugate melflufen was investigated in patient-derived HGOSex vivomodels and cell lines. The kinetics of apoptosis and necrosis induced by melflufen and doxorubicin were compared. Anti-neoplastic effects of melflufen were investigatedin vivo. Results: ElevatedANPEPexpression in diagnostic biopsies of HGOS patients was found to significantly reduce metastasis-free survival. In drug sensitivity assays, melflufen has shown an anti-proliferative effect in HGOSex vivosamples and cell lines, including those resistant to methotrexate, etoposide, doxorubicin, and PARP inhibitors. Further, HGOS cells treated with melflufen displayed a rapid induction of apoptosis and this sensitivity correlated with high expression ofANPEP. In combination treatments, melflufen demonstrated synergy with doxorubicin in killing HGOS cells. Finally, Melflufen displayed anti-tumor growth and anti-metastatic effectsin vivo. Conclusion: This study may pave the way for use of melflufen as an adjuvant to doxorubicin in improving the therapeutic efficacy for the treatment of metastatic HGOS.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

aminopeptidase
chemotherapy
melflufen
metastasis
osteosarcoma

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view